Review Article
Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Table 3
Recommended clinical endpoints for trials in patients with malignant melanoma, non-small cell lung cancer, or renal cell carcinoma.
| Malignant melanoma
[17] | NSCLC
[18, 19] | RCC
[20, 21] |
| | Overall survivala | Disease stability | Median overall survival |
| | Progression-free survival | Growth modulation index | Median progression-free survival |
| | Quality of life | Median overall survival | Response rate |
| | | Median progression-free survival | |
| | | Time to progression | |
|
|
The article did not specify median or mean OS.
|
